 Is buprenorphine that good?  Is medical management (MM) that good?  Is counseling that ineffective for this population?  Have the studies been designed.

Slides:



Advertisements
Similar presentations
Cognitive Behavioral Therapy and Naltrexone for Cocaine Dependence Joy M. Schmitz, Ph.D. Substance Abuse Research Center University of Texas Medical School.
Advertisements

What is the evidence for time limiting addiction treatment?
Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
Community-based Clinical Trials: Site Variation and Adoption of Innovation Dennis McCarty, PhD Allie Buti, MPH Lynn Kunkel, MS, CCRP Holly Fussell, PhD.
Models of Evaluation of Addiction Treatment Outcome Post-Treatment vs. During Treatment Evaluation of Effectiveness.
 William Frank Barker, LPC, MAC Diane Diver, LMSW, CAC II.
Principles of Drug Addiction Treatment: What Works with Offenders? Rita Dries July 2006.
Conceptual, Methodological and Practical Issues in the Recruitment and Retention of Participants OBSSR’s NIH Summer Institute on Behavioral and Social.
Addiction UNIT 4: PSYA4 Content The Psychology of Addictive Behaviour Models of Addictive Behaviour  Biological, cognitive and.
How much would it cost me to buy a day’s abstinence? Behaviour therapies in the addictions John Marsden, Ph.D. Division of Psychological Medicine & Psychiatry.
Motivational Interviewing to Improve Treatment Engagement and Outcome* The effect of one session on retention Research findings from the NIDA Clinical.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.
Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.
Evaluating Cocaine Use Outcome Measures: Relationships with Long Term Cocaine Use and Functioning Brian D. Kiluk, Ph.D. Kathleen M. Carroll, Ph.D. Yale.
TREATING SPECIAL POPULATIONS. OVERVIEW Tobacco Treatment Smoking Outcomes Co-occurring Disorders Integration Tobacco Prevention.
CYT Family Sessions Impact on CYT Process and Outcome Susan H. Godley, Rodney Funk, Michael L. Dennis, & Mark D. Godley, Chestnut Health Systems.
Addressing Crystal Methamphetamine Use Among Gay and Bisexual Men: A Treatment Center’s Response Joe Ruggiero, Ph.D. –Director, Outpatient Services The.
Have We Evaluated Addiction Treatment Correctly? Implications From a Chronic Care Perspective I.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Psychopharmacotherapy in Correctional Institutions Robert P. Schwartz, M.D. Friends Research Institute Supported by NIDA R01 DA (PI: Kinlock)
MIEDAR, PAMI and BEYOND Maxine Stitzer, Ph.D. Johns Hopkins SOM APHA Symposium Denver, CO November 10, 2010.
A secondary analysis of a study of 152 subjects aged seeking treatment for opioid dependence were randomized to 2 week detoxification with buprenorphine/naloxone.
Low-Cost Contingency Management in Community Settings
Practical Application of Contingency Management Michael J. McCann, MA Matrix Institute on Addictions.
SUBSTANCE USE DISORDERS GENERAL METHODS OF TREATMENT Inpatient Detoxification and Rehabilitation Outpatient Individual, Couple, or Family Counseling Self-help.
Attractive Addiction Treatment...? Can we make addiction treatment engaging?
Kathleen Carroll & Brian Kiluk Division of Substance Abuse Yale University School of Medicine Supported by NIDA Supplement to R01 DA15969 and P50 DA09241,
NIDA Grants: U10DA015831, K24DA022288, U10DA020024, K23DA022297, U10DA Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction.
Evidence-Based Practice: Psychosocial Interventions Maxine Stitzer, Ph.D. Johns Hopkins Univ SOM NIDA Blending Conference June 3, 2008 Cincinnati, Ohio.
Contingency Management in Problem Gambling Treatment Jeremiah Weinstock, Ph.D. University of Connecticut Health Center Farmington, CT USA.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
C:\laam\lamAPA.ppt 8/04/98 Heroin Addiction Treatment: A Comparison of Methadone and LAAM M. Douglas Anglin, Ph.D. Douglas Longshore, Ph.D. Jeffrey J.
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
The NIDA Clinical Trials is conducting the Prescription Opioid Addiction Treatment Study (POATS) – a multi- site trial examining different lengths and.
Sophie Lanzkron, MD, MHS Associate Professor of Medicine and Oncology Johns Hopkins School of Medicine.
Acceptance and Commitment Therapy (ACT) for Substance Use Disorder | Qualitative Review Acceptance and Commitment Therapy (ACT) for Substance Use Disorder.
 Copy: few empirical studies compared to other treatments  Eysenck- reviewed 2 studies, incorporating waiting list controls, which showed that 66% of.
PROFESSOR RONA MOSS-MORRIS ADHERENCE TO PSYCHOLOGICAL INTERVENTIONS IN MS.
1 Implementing and Sustaining MDFT in Practice Cynthia Rowe, PhD., Howard A. Liddle, Ed.D., Gayle A. Dakof, Ph.D., Craig Henderson, Ph.D., Alina Gonzalez,
Abstinence Incentives for Methadone Maintained Stimulant Users: Outcomes for Those Testing Stimulant Positive vs Negative at Study Intake Maxine L. Stitzer.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
1 Improving SUD Continuity of Care: Bringing Science to Practice Steven J. Lash, Ph.D. Associate Professor of Psychiatry and Neurobehavioral Science, Salem.
Abstinence Incentive Effects in Psychosocial Counseling Patients Testing Stimulant Positive vs Negative at Treatment Entry Maxine L. Stitzer Johns Hopkins.
California Addiction Training and Education Series Jeanne L. Obert, MFT, MSM Executive Director, Matrix Institute on Addictions Methamphetamine Behavioral.
BUPRENORPHINE TREATMENT: A Training For Addiction Professionals BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module.
Partnership for Advancing Recovery in Kentucky Using Technology for Continuing Care: Opening the Cage Door July 16, 2008 By David Mathews, Ph.D. Will press.
Relational Discord at Conclusion of Treatment Predicts Future Substance Use for Partnered Patients Wayne H. Denton, MD, PhD; Paul A. Nakonezny, PhD; Bryon.
Effectiveness, Quality, Performance : What’s the Difference? & How do you use them?
TREATMENT OF SUBSTANCE USE DISORDERS TX myths 1. Nothing works 2. One approach is superior to all others (“one true light” tradition) 3. All treatment.
Combined Pharmacological and Behavioral Therapy and HIV Risk Reduction Jennifer Schroeder, David Epstein, Katherine Belendiuk, Jessica Willner-Reid, John.
Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Predictors of study retention in addiction treatment trials KORTE JE 1, MAGRUDER KM 1,2, KILLEEN TK 1, SONNE SC 1, SAMPSON RR 1 and BRADY KT 1,2 1. Medical.
Clinical Trial Finds That While Buprenorphine-Naloxone Maintenance Reduced Other Opioid Use Among Those Dependent on Prescription Opioids, 91% Were Not.
Background and Rationale for COMBINE A Multisite Clinical Trial Sponsored by National Institute on Alcohol Abuse and Alcoholism NIH, DHHS Margaret E. Mattson,
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
Practical Application of Contingency Management Michael J. McCann, MA Matrix Institute on Addictions.
Buckinghamshire Healthy Minds Dr John Pimm, Clinical Lead Madhur Virathajenman Deputy Clinical Lead Thanks to David M Clark, National Clinical Advisor.
 Aims to help someone manage their problems by changing how they think and act  CBT encourages people to talk about: - how people think about themselves,
Methadone maintenance in Michigan: Five years of data using a contingency management approach Gary Rhodes, M.A., L.L.P. Golfo Tzilos, M.A. Mark Greenwald,
Date of download: 6/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Comparison of Contingency Management and Cognitive-Behavioral.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
One-Year Post-Treatment COMBINE Study Drinking Outcomes Dennis M. Donovan, Ph.D. for the COMBINE Study Research Group Research Society on Alcoholism Baltimore,
People with chronic pain are often prescribed methadone, a type of analgesic medicine to reduce pain. This medicine is also given.
Predictors of study retention in drug abuse treatment trials
Here Is Some More About Drug Addiction Treatment
CLINICAL INTRO TO: OPIOID ABUSE AMONGST PEOPLE EXPERIENCING HOMELESSNESS TYLER GRAY, MD HEALTHCARE FOR THE HOMELESS, BALTIMORE, MD.
Tri-Service Buprenorphine Training
Maintenance Treatment
Presentation transcript:

 Is buprenorphine that good?  Is medical management (MM) that good?  Is counseling that ineffective for this population?  Have the studies been designed properly?  What are the minimal requirements for counseling and good enough outcomes?

Why would everything we’ve learned about treating opioid dependence not apply to buprenorphine?

McLellan et al 1993

Hser et al., under review

MMMM+CBT MMMM+CBT Randomized 7170 Protective transfer or MMP 28 (39%)19 (27%) Missed visits 1124 Retained/success at 24 weeks (12 weeks after CBT stopped) 45%39% *6/12 sessions attended Supervision, no fidelity testing

CBTCM CBT+CM NT Randomized Completed treatment phase 16 weeks 37/53=69%35/49=71%34/49=69%28/51=54% CBT and CM stop Complete medication phase (32 weeks) 26/53=49%28/49=57%24/49=49%22/51=43% **Payments for assessments, including urines, CM reinforcement for opioid-negative urines only, no data on CBT fidelity, 73% compliance

MMMM + Counseling Randomized Success Phase 1 (12 weeks) 24 (7%)19 (6%) Start phase Success Phase 2 (24 weeks) 84 (47%)93 (52%) Success at post taper follow- up 13 (7%)18 (10%)

MM+ CMMM+CM+TES Randomized7892 Retained/success at 12 weeks 64%80% ** No follow-up reported Why were these outcomes so much better?

Bup + Standard careBup + Therapist CRABup + Computer CRA (TES) Randomized45 Retained at 24 weeks 58%53%62% Negative urines (opioids and cocaine) 57%73%70% Why were these outcomes so much better?

Reason% Discharge involuntarily/conflict with staff24% Discharge for missing too many days17% Program conflicts with other obligations (work, home) 17% Sought another provider14% Discharged due to too many positive urines9% Incarcerated7% Did not like buprenorphine4% Financial4% Wanted to keep using drugs4% Finished treatment successfully4%

Anxiety Pain Cocaine

Core principles: CBT4CBT development

Demo at CBT4CBT.com

Overview: CBT4CBT methadone trial Carroll et al., Am J Psych. 2014

Carroll et al., AJP, 2014

Kiluk et al, Addiction, 2010 Better response

A dherence A ttendance A bstinence A lternate activities A ccessing support

Is medical management (MM) that good? Compared to nothing, of course Moderate response, high attrition, high relapse implies significant room for improvement (floor, not ceiling effects) MM not scalable, nor representative of usual care in many settings Many providers new to addiction may be uncomfortable providing MM, access to addiction expertise seen as significant barrier

Is counseling ineffective for this population? No behavioral therapy yet tested without MM Tests of CM, CBT not done in accordance with current with methodological standards (targeting compliance, cocaine, other behaviors) Different models need to be considered Stepped models Technology based models Treating to success

Have the studies been designed properly? Highly unusual for CM not to be effective Cannot conclude counseling not effective for bup without significant MM Consider outcomes other than ‘retention = success’ What are the minimal requirements for counseling and good enough outcomes?

Supported by NIDA P50 DA09241, R37 DA15969, U10 DA015831, R01 DA035058, R01 DA03069 & NIAAA AA Psychotherapy Development Center website (training videos and resources, manuals, datasets): pdc.yale.edu CBT4CBT demo, etc at: CBT4CBT.com